Extending anti-clotting drugs beyond the initial treatment period of at least 90 days after a first blood clot is linked to lower rates of new clots developing compared with stopping treatment, finds ...

An experimental drug designed to block blood-clotting proteins may lower the risk of recurrent strokes, according to a dose-finding trial published in The Lancet Neurology. More than 795,000 people in ...

Clotting disorders can be treated by infusing patients with clotting proteins they lack, or with drugs that replace the function of these proteins. Gene therapies may soon become another option.

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, according to a preliminary ...

If you’re being treated for a type of blood clot called a deep vein thrombosis (DVT), your doctor may have told you to watch your intake of things high in vitamin K, like spinach, kale, and even green ...

Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Administration Bureau of Macao Special ...